Cargando…

Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?

Background: Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disease in Australia and is recognised to play a role in the development of hepatocellular carcinoma (HCC). There are no clear guidelines regarding screening for HCC in NAFLD. The aim of this retrospective stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Xuan-vinh Kevin, Zhang, Jason, Chin, Ken Lee, Bloom, Stephen, Nicoll, Amanda J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504716/
https://www.ncbi.nlm.nih.gov/pubmed/36145251
http://dx.doi.org/10.3390/nu14183875
_version_ 1784796286874025984
author Nguyen, Xuan-vinh Kevin
Zhang, Jason
Chin, Ken Lee
Bloom, Stephen
Nicoll, Amanda J.
author_facet Nguyen, Xuan-vinh Kevin
Zhang, Jason
Chin, Ken Lee
Bloom, Stephen
Nicoll, Amanda J.
author_sort Nguyen, Xuan-vinh Kevin
collection PubMed
description Background: Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disease in Australia and is recognised to play a role in the development of hepatocellular carcinoma (HCC). There are no clear guidelines regarding screening for HCC in NAFLD. The aim of this retrospective study was to compare the characteristics and survival rates of NAFLD-HCC to patients with non-NAFLD-HCC to help guide future research in this area. Methods: A total of 152 HCC patients with either NAFLD (n = 36) or non-NAFLD (n = 116) were retrospectively analysed from the HCC database and medical records. Chi-square and independent t-test were used to compare baseline characteristics and Kaplan–Meier curves and Cox models were used for survival analysis. Results: Patients with NAFLD-HCC were more likely to be diagnosed due to symptoms rather than through screening, and at an older age, compared with non-NAFLD HCC. The median survival rates were lower in NAFLD-HCC (17.2 months) than in those with non-NAFLD-HCC (23.5 months). Conclusion: There is a rise in the number of HCC cases in patients with NAFLD, and this has significant implications for hepatologists as they are presented with more advanced diseases and have poorer outcomes. Future studies on HCC will need to identify this group earlier in order to have an impact on the HCC survival rate.
format Online
Article
Text
id pubmed-9504716
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95047162022-09-24 Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver? Nguyen, Xuan-vinh Kevin Zhang, Jason Chin, Ken Lee Bloom, Stephen Nicoll, Amanda J. Nutrients Article Background: Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disease in Australia and is recognised to play a role in the development of hepatocellular carcinoma (HCC). There are no clear guidelines regarding screening for HCC in NAFLD. The aim of this retrospective study was to compare the characteristics and survival rates of NAFLD-HCC to patients with non-NAFLD-HCC to help guide future research in this area. Methods: A total of 152 HCC patients with either NAFLD (n = 36) or non-NAFLD (n = 116) were retrospectively analysed from the HCC database and medical records. Chi-square and independent t-test were used to compare baseline characteristics and Kaplan–Meier curves and Cox models were used for survival analysis. Results: Patients with NAFLD-HCC were more likely to be diagnosed due to symptoms rather than through screening, and at an older age, compared with non-NAFLD HCC. The median survival rates were lower in NAFLD-HCC (17.2 months) than in those with non-NAFLD-HCC (23.5 months). Conclusion: There is a rise in the number of HCC cases in patients with NAFLD, and this has significant implications for hepatologists as they are presented with more advanced diseases and have poorer outcomes. Future studies on HCC will need to identify this group earlier in order to have an impact on the HCC survival rate. MDPI 2022-09-19 /pmc/articles/PMC9504716/ /pubmed/36145251 http://dx.doi.org/10.3390/nu14183875 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nguyen, Xuan-vinh Kevin
Zhang, Jason
Chin, Ken Lee
Bloom, Stephen
Nicoll, Amanda J.
Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?
title Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?
title_full Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?
title_fullStr Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?
title_full_unstemmed Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?
title_short Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?
title_sort is hepatocellular carcinoma in fatty liver different to non-fatty liver?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504716/
https://www.ncbi.nlm.nih.gov/pubmed/36145251
http://dx.doi.org/10.3390/nu14183875
work_keys_str_mv AT nguyenxuanvinhkevin ishepatocellularcarcinomainfattyliverdifferenttononfattyliver
AT zhangjason ishepatocellularcarcinomainfattyliverdifferenttononfattyliver
AT chinkenlee ishepatocellularcarcinomainfattyliverdifferenttononfattyliver
AT bloomstephen ishepatocellularcarcinomainfattyliverdifferenttononfattyliver
AT nicollamandaj ishepatocellularcarcinomainfattyliverdifferenttononfattyliver